2
Participants
Start Date
September 22, 2020
Primary Completion Date
June 30, 2021
Study Completion Date
March 1, 2022
Acalabrutinib
Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.
Rituximab
Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
Ifosfamide
Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.
Carboplatin
Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
Etoposide
Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
University of Miami, Miami
Collaborators (1)
AstraZeneca
INDUSTRY
University of Miami
OTHER